FRI0367 Association of vitality and subsequent physical functioning in systemic lupus erythematosus: analysis of data from the german lula cohort 2002 – 2013. (12th June 2018)

• Record Type: Journal Article
• Authors: Mucke, J.; Chehab, G.; Fischer-Betz, R.; Richter, J.; Winkler-Rohlfing, B.; Schneider, M.; Brinks, R.
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 2
• Page Start: 718
• Page End: 718
• Publication Date: 2018-06-12
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-eular.4889
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Fatigue, defined as loss of vitality, is a major burden in patients with systemic lupus erythematosus (SLE). It is well-known from cross-sectional studies that fatigue is associated with physical functioning (PF) whereas the effect of fatigue on subsequent PF has not yet been further looked on. Methods: Data from the German Lupus-Langzeitstudie (LuLa) cohort was used to explore the effect of self-reported vitality on PF. The ongoing LuLa study comprises patients from the German SLE self-help group. The current analysis uses data from 2002 to 2013. We looked for associations between the PF score (outcome) and the vitality score of the SF-12 questionnaire in one to four years preceding the outcome. Statistical analysis was accomplished by a linear mixed regression model (LMM) adjusting for the potential confounders age, sex, disease duration and disease activity as surveyed by the Systemic Lupus Activity Questionnaire score (SLAQ). Results: 1511 patients (93.3% women) provided data with a total of 7841 person-years of observation. Median age at study entry was 46 (interquartile range: 37 to 57). The table 1 shows the regression coefficients of the vitality score (and 95% confidence intervals, CI) estimated by the LMM without and with adjusting for age, sex, disease duration and SLAQ. Conclusions: We found evidence that self-reported vitality in patients with SLE is associated with PF in the subsequent years. The data indicate a "window of opportunity" for treating fatigue symptoms of up to four years for maintenance of PF. Disclosure of Interest: J. Mucke: None declared, G. Chehab Grant/research support from: GlaxoSmithKline and UCB Pharma for performing the LuLa-study, R. Fischer-Betz Grant/research support from: GlaxoSmithKline and UCB Pharma for performing the LuLa-study, J. Richter Grant/research support from: GlaxoSmithKline and UCB Pharma for performing the LuLa-study, B. Winkler-Rohlfing: None declared, M. Schneider Grant/research support from: GlaxoSmithKline and UCB Pharma for performing the LuLa-study, R. Brinks: None declared